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Background: The CD40 ligand (CD40L) is a member
of the tumor necrosis factor (TNF) family of proteins and
is transiently expressed on the surface of activated T cells.
The binding of CD40L to CD40, which is expressed on
the surface of B cells, provides a critical and unique path-
way of cellular activation resulting in antibody isotype
switching, regulation of apoptosis, and B cell proliferation
and differentiation. Naturally occurring mutations of
CD40L result in the clinical hyper-IgM syndrome, char-
acterized by an inability to produce immunoglobulins of
the IgG, IgA and IgE isotypes.
Results: We have determined the crystal structure of a
soluble extracellular fragment of human CD40L to 2 A
resolution and with an R factor of 21.8%. Although the
molecule forms a trimer similar to that found for other
members of the TNF family, such as TNFat and lympho-
toxin-a, and exhibits a similar overall fold, there are
considerable differences in several loops including those
predicted to be involved in CD40 binding.
Conclusions: The structure suggests that most of the
hyper-IgM syndrome mutations affect the folding and sta-
bility of the molecule rather than the CD40-binding site
directly. Despite the fact that the hyper-IgM syndrome
mutations are dispersed in the primary sequence, a large
fraction of them are clustered in space in the vicinity of a
surface loop, close to the predicted CD40-binding site.
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Introduction
The immune system is an ensemble of many complex
processes, many of which involve cell-cell communica-
tion. This process of communication is mediated by both
secreted and cell-surface-expressed cytokine molecules.
Binding of the cytokines on appropriate receptors of cells
are events that direct cell behaviour. CD40 ligand
(CD40L), also known as T-B activating molecule
(TBAM), TNF-related activation protein (TRAP) or
gp39, is a 33 kDa, type II membrane glycoprotein
expressed on the surface of activated CD4+ T cells which
has been shown to mediate functional T and B cell inter-
actions [1-5]. Binding of T cell CD40L to its cognate
receptor, CD40, expressed on the surface of B cells has
several effects, including activation of antibody isotype
switching, prevention of B cell apoptosis to establish
immunological memory, germinal center formation in
lymph nodes, modulation of cytokine production in acti-
vated B cells and B cell proliferation and differentiation
[6-10]. Several mutations of CD40L are known to cause
a severe immunodeficiency, linked to the X chromo-
some, known as hyper-IgM syndrome (HIGMS), which
is characterized by normal or elevated levels of
immunoglobulin (Ig) M, but the absence or low levels of
IgG, IgA and IgE in serum [11-16]. A murine CD40L
gene 'knockout' also lacks expression of IgG, IgA and
IgE similar to HIGMS in man [9,10]. These observations
suggest that CD40 signaling is absolutely required for
IgG, IgA and IgE production and that this function is
non-redundant with other signaling/adhesion pathways.
Studies show that CD40L may play a role in certain
diseases such as arthritis [17], lupus [18], Hodgkin's
lymphoma [19] and viral infections [20]. Thus, it is
apparent that interfering with the CD40L-CD40
interaction may have important therapeutic applications.
Early studies [21-23] showed that CD40L is a member of
the tumor necrosis factor (TNF) family of cytokines.
Other members of this family include TNFot, lympho-
toxin-oa (LTca) (also known as TNF3), LT,3, Fas ligand,
CD30L, CD27L and 4-1BBL. Crystal structures are
available for two members of this family, TNFoa [24,25]
and LTao [26]. Both structures show that these molecules
are homotrimers and that each monomer folds as a
,3 sheet sandwich of Greek key topology. Despite their
relatively low sequence identity (30.6%), TNFa( and LT(x
share a high degree of structural homology. CD40L is
expected to consist of a 22-residue intracellular N-termi-
nal domain, a short transmembrane segment, a relatively
long, 65-residue extracellular 'stalk' and a globular TNF-
like extracellular domain of about 150 residues at the
C-terminal end.
The TNF-like CD40L domain has only 24.7% sequence
identity with LT and 27.3% identity with TNFa. It has
been proposed that other members of this family share
similar three-dimensional structures [27]. In addition, the
crystal structure of the complex of LTa with its receptor,
*Corresponding author.
© Current Biology Ltd ISSN 0969-2126 1031
1032 Structure 1995, Vol 3 No 10
TNFR-55, has been determined [28] and provides a
framework for modeling the ligand-receptor interaction
of other members of the TNF family. The complex
consists of three elongated receptor molecules bound in
the LTot intersubunit grooves. Each receptor molecule
consists of four concatenated domains that in turn form
separate folded units. Only the second and third TNFR
domains contact LTa directly. It has been proposed that
the binding of three receptors to one LTa molecule
brings together the cytoplasmic domains of the receptors
and results in signaling.
In this report we describe the crystal structure of a func-
tional soluble fragment of CD40L containing residues
Glyll116-Leu261 of the extracellular domain. The struc-
ture of this fragment was determined at 2 A resolution by
the method of molecular replacement. We also discuss
insights that the structure provides into the CD40L-
CD40 interaction and the nature of hyper-IgM mutations.
Results and discussion
Description of the structure
Almost all of residues of CD40L, except for residues
116-119 of the N terminus, are well defined in the final
2Fo-F c electron-density map (Fig. 1). There are areas of
weak density for residues 182-186 and 210-220. The
current model consists of 142 amino acid residues and
95 water molecules with a crystallographic R factor of
21.8% and an Rfree of 29.1% for data between 7.5 A
and 2 A. The Ramachandran diagram shows that 140
out of the 142 amino acid residues have (q,) angles
within the allowed regions. The exceptions are residues
Cys218, which is involved in formation of a disulfide
bridge, and Lysl43.
CD40L folds as a sandwich of two [3 sheets with jellyroll
or Greek key topology (Fig. 2). The dimensions of the
molecule are 25 Ax30 Ax50 A. The overall fold is
similar to that of TNFa and LTa (Fig. 3). In our
description, the notation of [26] is used for the 3 strands
and other structural features. One sheet consists of
strands A"AHCF and the other of strands B'BGDE. To
assess the degree of structural similarity between TNFa,
LTot and CD40L, we aligned their sequences so as to
maximize the overlap of equivalent -strand residues.
The equivalent Ca atoms from the 3 strands were then
used to superimpose the molecular structures. The root
mean square (rms) positional deviation of 86 equivalent
Ca atoms of superimposed TNFa and CD40L mol-
ecules is 1.10 A. In the case of the LTa/CD40L pair, the
rms deviation for the 100 equivalent Ca atoms is 1.03 A.
The positions of the residues are highly conserved in the
core and 3-strand regions but differ significantly in cer-
tain loops, such as the AA", CD and EF loops. An align-
ment of the TNFa, LTa and CD40L sequences, based
on the best structural superimpositions, is shown in Fig-
ure 4. Most residues of the hydrophobic core of CD40L
maintain the identity or the character encountered in the
equivalent residues of TNFa and LTa. There are local,
compensatory, conformational changes to accommodate
side-chain changes, such as the substitution of Leu33 of
LTa to Val136 in CD40L which results in a shift of the
side chain of Leul61 to fill the empty space.
Three CD40L molecules form a trimer similar to that
observed in the crystal structures of TNFa and LTa. The
trimer has the shape of a truncated pyramid. The three-
fold axis of the trimer is approximately parallel to the
[3 strands of each subunit. The interface between the sub-
units is formed mainly by two tyrosines, two histidines
and one leucine. Thus, the 'aromatic tiling' observed in
LTa is not as prevalent in CD40L. Tyrl70 and His224
from each monomer form an unusual cluster of two tri-
ads along the threefold axis of the trimer (Fig. lb).
The crystal packing of CD40L trimers is displayed in
Figure 5. Each CD40L monomer forms one crystal
Fig. 1. Representative regions of the
final 2F0-Fc electron density map con-
toured at 2.5a. (a) Residues in the vicin-
ity of the CD40 binding site. (b) View of
a cluster of three tyrosine and three his-
tidine residues formed in the vicinity of
the center of the trimer. The threefold
axis is vertical.
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Fig. 2. The three-dimensional structure of the monomer of human CD40L. (a) Stereo drawing of CD40L Ca backbone. Several residues
are numbered and the termini are labeled. (b) Ribbon representation and secondary structure assignment of CD40L. Strands are labeled
following the notation of [26].
Fig. 3. Stereo diagram of superimposed
Ca backbones of TNFa (green), LTa
(blue) and CD40L (red) crystal struc-
tures. The view is approximately the
same as in Figure 2.
Fig. 4. Sequence alignment of the TNF-
like domains of TNFa, LTa and CD40L
based on structural considerations. The
secondary structure assignment and
numbering at the top of the figure corre-
spond to CD40L. Asterisks in line 1
indicate residues of the LTa sequence
that are involved in contacts with the
TNF receptor. In line 2, CD40L residues
for which mutations affect CD40 bind-
ing are indicated with a minus (-) sign,
while those at which mutations have a
minimal effect or no effect on CD40
binding are indicated by a plus (+) sign.
-A- -A"- -B' - -B- - -D-
116 125 135 145 155 165 175 185 195
NFtm RIP VAHV PV1Q lq&NMMMPLAz ELED NLVVPYL~XIYSQ7L8WGIP STHV LIlSIAV
LTX TKP AAHLIEPSKO LNRERAMMW SISN NL5VPSGrVYSVVFS YLANPLESS
cD40L QIMIAM WIsrASSrSV1Q AM3Nrvi omrmalnQr --S --OUMSECI
1 * ** * ******** *** ** * *
2 . . . .... +. . ................................ ........
-E-- -G- -H-
205 215 225 235 245 255
1-£ s__n%~glCYEPupMMl~~ YtAGV FGIIAL
LTU QYPFHVPIFSSML Y P4En PSSIOA]L4SIVHGYlSPS VF FI(FPAL
CD40L RFE RI LLRUAAWIS AMKC PCIH1TGASVFVNVTDPSOVGQ S2r GSPIGLLL
1 **** * * * * * * * * ***** *
2 .4+ --- +... -... +..+
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contact that involves loops DE (residues 198-201), FG
(232-233) and BC (164-166) from one molecule and
loops CD (182-186), AA" (131-135) and GH (245-246)
from the neighboring molecule. Sixteen water molecules
are involved in the formation of the contact.
The CD and EF loops of CD40L at the 'top' of the
molecule are shorter than those of TNFot and LTot.
However, despite its shorter length, the CD loop con-
tains 1.5 turns of a helix in a similar manner to the
equivalent loop in LTa. Also analogous to LToL, regions
of poor electron density occur within these loops that
may indicate disorder. In addition, a plot of the tempera-
ture factors (Fig. 6) suggests that the CD and EF loops
are the most mobile parts of the molecule. The C and F
strands are linked by a disulfide bridge between Cys178
and Cys218 that may play a role in stabilizing the top the
molecule. A disulfide bridge is also present in TNFot but
it is located at a different position. Although the AA"
loop does not differ much between TNFca and LTa, in
CD40L it has a very different structure: it is shifted away
from the CD40-binding site relative to TNFet and LTa.
The unusual conformation of the AA" loop may be
related to its extensive participation in the crystal contact.
A short 310-helical structure is found within the GH
loop and a 3 bulge occurs in the middle of strand E. The
N and C termini lie close to each other at the base of the
trimer. Residues 116-119 of the N terminus of the
construct are poorly defined in the electron-density map,
therefore the first well ordered residue is Prol20.
Residues 116-119 presumably constitute part of the stalk
connecting the globular domain to the transmembrane
segment. This 65-residue stalk is unusually long
compared with the equivalent segments in other
inembers of the TNF family.
A single glycosylation site is predicted from analysis of
the CD40L sequence. Biochemical experiments (data not
shown) revealed that residue Asn240 of the CD40L
protein used for the crystallization has an N-linked
carbohydrate attached to it. A 2F -F c map shows
electron density in the vicinity of the side chain of
Asn240 which presumably corresponds to the attached
carbohydrate. However, because the density is not well
defined, the current model contains no carbohydrate
atoms at this position.
Binding site
By analogy with the LTa-TNFR complex crystal struc-
ture, the CD40-binding site consists of a shallow groove
formed between two monomers. The activation complex
of CD40L-CD40 is expected to be similar to the
LTot-TNFR complex. On the basis of the linkage dia-
gram in [28], showing which residue of LTax interacts
with which residue of TNFR, stretches of the CD40L
sequence that are likely to constitute the binding site of
CD40L can be inferred (Fig. 4). The binding site is
expected to contain residues mostly from the AA" and
DE loops. In addition, residues from the CD and GH
loops and 3 strands C, D, G and H are expected to be
involved in CD40 binding. Virtually no sequence con-
servation exists between CD40L and LTot or TNFot in
these regions. Although Serl31 of the AA" loop appears
to be conserved in the sequence alignment, the structural
superimposition shows that it is relatively distant from the
equivalent position (Ser38) in LTa. The Tyr145 side
chain of the AA" loop of CD40L is disordered but is
found in an equivalent position to Arg51 of LTa and,
like Arg51 in the LTot-TNFR complex, may have an
extended and well-defined conformation in the com-
plex. On the DE loop, only Phe201 is conserved (equiv-
alent to Phel 10 of LTa). Interestingly, Phe201 adopts a
very similar conformation to that of Phel 10 in the
LTa-TNFR complex, whereas in the uncomplexed
LToL, PhellO10 adopts a quite different conformation. The
Arg200 side chain in the DE loop is involved in a crystal
contact. As mentioned earlier, the conformation of loops
DE, AA" and GH is likely to be affected by the crystal
contact thus it is expected that their structure will be dif-
ferent in the complex. The conformational changes asso-
ciated with complex formation in the case of LTa,
although minor, may be indicative of the magnitude of
changes that occur upon CD40 binding to CD40L.
A mixture of both hydrophobic and hydrophilic residues
form the surface of the binding site. The LTot-TNFR
binding interface can be considered as separate upper and
lower regions [28]. In a similar manner to LTa, the
Fig. 5. Stereoview of the crystal packing
of CD40L. The unit cell is also dis-
played. The three CD40L trimers shown
pack with their threefold axes parallel to
the c axis of the unit cell.
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Fig. 6. Graph of temperature factors of main-chain atoms as a
function of residue number.
upper region in CD40L has more hydrophobic and
non-charged polar residues than the lower region.
Arg207 seems to be a key residue, lying in the area where
the upper and lower regions connect. The Arg207 side
chain adopts an extended conformation pointing towards
the putative location of the CD40 receptor and is sur-
rounded by three surface-exposed hydrophobic residues
and a serine residue (Ser192). Two of the hydrophobic
residues (Ilel90 and Phe253) belong to the neighboring
subunit, whereas Ile204 is from the same subunit. Murine
CD40L has a lysine in the position equivalent to that of
Arg207 of human CD40L and this lysine also seems
likely to be surrounded by hydrophobic residues [22].
The hydrophobic environment of the arginine may
amplify the strength of a possible electrostatic interaction
between this residue and an acidic residue of CD40.
Analysis of mutations
Mutagenesis studies on CD40L have shown that residues
Tyr145 and Lys143 are directly involved in CD40 bind-
ing [29]. The crystal structure shows that both residues
lie on the AA" loop and are surface-exposed (Figs 7,8).
The equivalent loop in the LTot-TNFR crystal structure
is involved in several ligand-receptor contacts suggesting
similarities in binding. Tyr145 lies at the corner of the
loop and its side chain has no visible electron density
which suggests that it is disordered. Atom NC1 of Lysl43
forms a hydrogen bond with O1 of Glu129 (Fig. la).
The 2Fo-F c electron-density map also shows that the side
chain of Lys143 has an additional conformation. Ser128
and Glu129, two residues involved in the HIGMS muta-
tion Serl28-Arg,Glul29--Gly, lie close to Lys143 and
are well defined in the map. Ser128 is almost completely
buried and its side-chain hydroxyl group is within hydro-
gen-bonding distance of His249. It has been shown that
the Glu129-Gly substitution found in the HIGMS
mutation Ser128--Arg,Glul29--Gly affects a solvent-
accessible residue that might participate in binding to
CD40 [29]. One possible candidate for this exposed
residue is Lys143, and loss of its hydrogen bond to
Glu129 may destabilize its conformation resulting in
Fig. 7. Residues involved in hyper-lgM and designed mutations.
The side chains of residues that affect CD40 binding when
mutated are shown in red whilst those that have no affect are
shown in blue. The Ca backbone of the molecule is shown in
green. For clarity, only two of the three subunits are shown.
Fig. 8. The binding site for CD40 shown in a space-filling repre-
sentation. Those visible surface residues that affect CD40 binding
when mutated are shown in red, whilst those that had little or no
effect are shown in blue. The orientation of the molecule is the
same as in Figure 7 and only two of the three subunits are shown.
reduced CD40 binding. Interestingly, all of these residues
(Serl28, Glu129, Lys143 and Tyr145) are conserved in
the murine CD40L sequence.
Five additional single-site mutations, in which residues
Serl31, Asnl80, Phe201, Glu202 and Asn240 (located at
the binding site) were substituted by alanine, established
that these residues are not critical for CD40 binding. In
addition, two other mutations at residue positions outside
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of the binding site (Thr135 and Asp243) were also shown
not to affect binding [29]. According to the structure,
Serl31 and Thr135 lie on the AA" loop and their side
chains are not exposed. Asn240, the site of glycosylation,
is exposed to the solvent. Because the attached sugar
would be expected to make Asn240 unavailable for inter-
action with CD40, we conclude that it is probably not
involved in CD40 binding, in agreement with the muta-
genesis results. Asp243 is a semi-exposed residue and it
makes a hydrogen bond to Asn186. Asn180 is an exposed
residue at the top of the molecule. Its side chain makes
hydrogen bonds to residues 183 and 216. Phe201 and
Glu202 both lie on the DE loop in the binding site area
and are exposed to the solvent.
The detrimental effects of several HIGMS mutations on
CD40L appear to be caused by destabilizing its structure.
For example, Trp140 is a large hydrophobic residue
buried inside the protein and removal of its side chain in
the HIGMS mutations Trpl40--Gly and Trpl40--Arg
will obviously lead to destabilization of the structure.
The valine affected by the Val126-4Ala mutation also
participates in forming the hydrophobic core. Leu155 is
not completely buried but lies in the middle of 13 strand
B. Introduction of proline at this position, as in the
Leul55-Pro HIGMS mutation, may disrupt the forma-
tion of the strand. The behavior of the HIGMS mutation
Ala235--Pro can be similarly explained. Substitution of
Gly144 in the HIGMS mutation Gly144--Glu may
result in loss of the conformational freedom necessary at
that position to form the corner of the AA" loop. Con-
sequently, the positioning of the adjacent residues,
Lys143 and Tyr145, which are known to be involved in
binding, is disrupted. An interesting observation is that
all of the above mentioned residues appear to be clus-
tered (Fig. 7): Trpl40, Leu155 and Val126 participate in
the formation of an area of the hydrophobic core par-
tially formed by strands A, A", B' and B. Lys143, Gly144
and Tyr145 are exposed surface residues of the AA" loop
lying very close to the above mentioned hydrophobic
residues. This suggests that the CD40-binding capacity is
very sensitive to perturbations in this area of CD40L.
HIGMS mutations Ala123--Glu, Gly227V-al and
Thr2l 1 -Asp affect residues that are involved in forma-
tion of the subunit interface. Ala123 lies near the bottom
of the trimer and is within van der Waals distance of
three hydrophobic residues (Leu168, Val228 and Leu261)
of the neighboring subunit. Gly227 packs against Tyr172
of the neighboring subunit and Thr211 lies on the EF
loop close to the intersubunit interface where it appears
to interact with Argl81 from the neighboring subunit.
Mutations that introduce larger side chains at these posi-
tions (e.g. Thr211ll-Asp) would be expected to disturb
the intersubunit packing and possibly prevent trimeriza-
tion. Thus, it appears that most of the single-site HIGMS
mutations affect the folding and stability of CD40L
rather than playing a direct role in CD40 binding. In
addition, mutations of only two of the nine targeted
surface residues appear to affect CD40 binding [29].
Biological implications
CD40 ligand (CD40L) is a T cell membrane-bound
pleiotropic cytokine of considerable biomedical
interest because of its involvement in important
immune system functions such as antibody isotype
switching and establishing immunological mem-
ory. These processes are associated with the bind-
ing of CD40L to CD40, a molecule expressed on
the surface of B cells. Naturally occurring muta-
tions of CD40L in humans result in a severe
immunodeficiency known as hyper-IgM syndrome
(HIGMS), a fact which provides evidence that the
function of CD40L is non-redundant.
The crystal structure of CD40L confirms that it is
a member of the tumor necrosis factor family of
ligands. The crystal structure of another member
of this family, lymphotoxin-a (LTa) complexed
with its receptor has been described and can be
used as a framework for understanding the
CD40L-CD40 interaction.
The CD40L structure suggests that most, if not all,
of the naturally occurring single-site HIGMS
mutations affect the folding and stability of the
protein rather than the binding site directly.
Indeed, more severe HIGMS mutations involving
deletions or other drastic changes would be
expected to perturb the structure much more than
single-site mutations. In addition, only two of the
six binding-site residues selected for mutagenesis
were found to be critical for CD40 binding. A
similar low frequency of hits was found in an
analogous mutational study of LTot [30]. This
observation raises the question of whether muta-
tions of individual CD40L binding-site residues are
generally sufficient to completely disrupt CD40L-
CD40 binding. If insufficient, CD40-mediated cel-
lular signaling will continue and the mutation will
be clinically undetectable. This behavior is consis-
tent with the fact that, in the LTca-receptor com-
plex structure, as many as 38 LTa residues are
involved in the binding interface. The interface is
quite extensive (520 A2 ) and is presumably of simi-
lar dimensions in the CD40L-CD40 complex. It is
expected, therefore, that each residue only con-
tributes a small fraction of the binding energy.
However, the interaction of the human growth
hormone with its receptor has also been shown to
involve a large surface area, yet relatively few key
residues contribute most of the binding energy
[31]. Obviously further mutational analysis, identi-
fication of additional HIGMS mutations and deter-
mination of the CD40L-CD40 complex structure
are required to resolve this issue conclusively.
Considering the complexity and overlap of the
various immune system processes, the fact that
CD40 signaling appears to be non-redundant
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suggests that inhibiting CD40L signaling may have
important therapeutic applications. The crystal
structure of CD40L presented here is expected to
be useful in the design of such therapeutic agents.
Materials and methods
Crystallization
Buffer chemicals were purchased from Fisher (Boston, MA).
Crystallization condition screenings were done with the Crystal
ScreenTM kit from Hampton Research (Riverside, CA). A
protein fragment of human CD40 ligand containing amino acid
residues Gly116 to the C-terminal residue Leu261 was
expressed in soluble form in Pichia pastoris yeast cells and puri-
fied by affinity chromatography. (Details of protein expression
and purification will be published elsewhere.) Based on
sequence homology, this fragment is expected to correspond to
the TNF-like region of CD40L. Biochemical analysis (unpub-
lished data) suggests that there is a single glycosylation site at the
residue Asn240. The attached carbohydrate is expected to be
N-linked high-mannose sugar of approximate molecular weight
3000 Da, however its exact chemical composition is currently
unknown. The protein stock was made available as a solution of
8 mg ml-' (-0.5 mM) CD40L in phosphate-buffered saline
(0.144 M Na 2HP0 4 , 0.056 M Na2HPO 4.H20, 1.5 M NaCI).
Crystals were grown by the vapor diffusion method [32]. In
order to find conditions of crystallization, an incomplete factor-
ial screen was set up [33]. In a typical experiment, protein solu-
tion was mixed with an equal volume of reservoir solution and
a drop of the mixture was suspended under a glass cover slip
over the reservoir solution. Crystals were grown out of 1.4 M
Na-citrate, 50 mM Na-HEPES, pH 7.5 reservoir solution.
They are cuboid, easy to reproduce and can reach maximum
dimensions of almost 1 mm on each side (the optimal concen-
tration of precipitant to get the biggest crystals is 1.2 M
Na-citrate). Variation of pH between 7 and 8 does not affect
crystal quality. Macroseeding techniques were also successful
but were not necessary to get crystals of sufficient quality.
Crystal composition was assayed after washing, dissolution in
water and SDS-PAGE. The gel showed a strong band of
-20 kDa and a much fainter band of 17 kDa. It was later shown
that the fainter band corresponds to non-glycosylated protein.
Data collection and processing
Crystals were mounted inside capillary tubes and tested for dif-
fraction capacity on the X-ray beam. Oscillation photographs
showed strong diffraction to high resolution. Initial inspection
of the photographs suggested an almost cubic lattice.
A large crystal (0.8x0.8x0.8 mm3) was equilibrated gradually
in a cryoprotectant solution of 20% glycerol, 1.2 M Na-citrate,
50 mM Na-HEPES, pH 7.5, mounted on a loop and immedi-
ately frozen in a -1500C liquid nitrogen gas stream. The
technique of freezing the crystals essentially immortalizes them
and produces a much higher quality data set. A native X-ray
data set, up to 1.75 A resolution, was collected by using a
Nicolet/Siemens multiwire area detector (Siemens, Inc.,
Karlsruhe, Germany). The data were integrated and reduced
using BUDDHA [34] and the CCP4 program package [35].
The data collection required about 5 days.
The systematic absences in the intensities of the data indicated
that the reflections could be indexed in a rhombohedral lattice
with approximate cell dimensions a=b=c=55 A and
ca=P=ry=91°. To assist calculations, a hexagonal unit cell was
defined instead with dimensions a=b=77.17 A, c=90.46 A,
-y=1200 . Merging of data allowed us to identify the space
group of the crystals. The Rmerge is 6.7% if space group R3 is
assumed, but 16.6% if space group R32 is assumed. Thus, we
concluded that the space group was R3. The data statistics sug-
gest that the data quality is high. Table 1 contains information
for the data set obtained.
Calculation of the Matthews volume [36] gives
VM=2 .97 A3 Da-' assuming one molecule per asymmetric unit
and a molecular weight equal to 20000 Da. Thus, it was not
clear initially whether there were one or two monomers in the
asymmetric unit.
Molecular replacement
All subsequent molecular replacement and refinement comput-
ing was done with the X-PLOR program package [37]. Mol-
ecular graphics manipulations were performed with QUANTA
software (Molecular Simulations Inc., Burlington, MA). Both
X-PLOR and QUANTA were run on a Silicon Graphics
Indigo 2 computer workstation (Silicon Graphics, Mountain
View, CA) .
To investigate whether non-crystallographic symmetry was
present, the self-rotation function was calculated with 8-4 A
data. A very strong peak was found for 4=90 ° , Jt=90 °, K=120
which obviously corresponds to the crystallographic threefold
axis. This is expected to coincide with the threefold axis of the
trimer of CD40L. In addition, weaker peaks appeared for
4=0° , qi=30 °, K=1800 and =0 0, qs=90, K=1800 and )=0O°,
t4=150°, K=120 ° corresponding to twofold axes perpendicular
to the threefold axis. As shown later, none of these axes corre-
sponded to non-crystallographic symmetry.
A three-dimensional model of the human CD40L was con-
structed by using the murine CD40L model [22] as a frame-
work, using QUANTA protein homology modeling software.
The murine CD40L model itself was based on the TNFot crys-
tal structure. The model was used as a probe for molecular
replacement calculations.
Table 1. Crystallographic and refinement data.
Symmetry R3
Unit cell a=b=77.17 A, c=90.46 A, ea=P= 9 0°, ==1 200
No. of crystals 1
Resolution 1.75 A
No. of reflections
measured 42 587
unique 15 693
Rmerge* 6.7%
Completeness
overall 77.1%
to 2.1 A 89.9%
I/it(1)
overall 6.5
1.75-1.84 A 3.9
Rworkt 21.8% (for 7.5-2 A data)
Rfreet 29.1%
Rms deviations
bonds 0.021 A
angles 3.9
*Rmerge=hi IhiIh I/hihi. t Rfree=Rwork=lFobs-Fcalcl/ Fobs
'
where 'free' and 'work' refer to the free and working data sets,
respectively.
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Calculation of the cross-rotation function by using a 2.50 angle
grid and 8-4 A data produced a strong peak 4.5cr above the
mean, at Euler angles 01=234.5 ° , 02=5.0, 03=234.5° . Rota-
tion of the model according to that solution and subsequent
generation of symmetry-related molecules corresponding to
the threefold crystallographic symmetry produces a trimer
with the threefold axis parallel to the z axis, as expected. The
exact rotation solution was found with Patterson correlation
refinement. No significant second peak was observed in the
rotation function.
In order to do the translation search, the model probe was
rotated according to the first peak of the rotation search and
translated so that the center of mass of the trimer would lie on
the z axis. This was assumed to be close to the expected posi-
tion because the threefold axis of the trimer appeared to lie on
the z axis of the unit cell. Initial attempts to find a clear peak in
the translation function on the xy plane failed. Trimmed model
probes, containing mostly core residues the structures of which
were more likely to be conserved among different members of
the TNF family, produced translation functions with a cluster-
ing of peaks at locations close to the expected ones. One of
those trimmed models containing all backbone atoms as well as
side-chain atoms for residues 123-127, 168-177, 205-208,
225-229 and 256-261 produced a peak with a correlation
coefficient of 3.3cr above the mean at x=0.053, y=0.0 53 . This
peak was the highest on the list of peaks and was close to the
expected position.
By generating symmetry-related molecules and displaying them
with computer graphics it was found that all the CD40L mol-
ecules in the unit cell packed satisfactorily and that there was
not enough space for a second molecule. Thus, we concluded
that there was only one molecule in the asymmetric unit. The
existence of twofold symmetry in the self-rotation function
appears to be a consequence of internal symmetry within the
molecule, possibly related to the high content of parallel
P strands. In fact, the self-rotation function calculated from
structure factors derived from the model shows peaks corre-
sponding to twofold symmetry.
Model building and crystallographic refinement
The paraml9.pro stereochemical parameter set of the
X-PLOR package was used for all refinement calculations. The
partial model that was used to find the solution of the transla-
tion function was subjected to rigid-body refinement by using
7.5-2.5 A data. The R and Rfree [38] factors after the initial
rigid-body refinement were 49.9% and 51.4%, respectively.
The test data set used for the calculation of Rfree contained
10% of the data. The partial model was subjected to 40 steps of
conventional positional refinement and a cycle of simulated
annealing with an initial temperature of 2500 K. The R and
Rfree factors dropped to 31.2% and 43.1%, respectively. To
reduce model bias, a partial model was used for map calculation
and refinement. The resolution range used was 7.5-2.5 A.
Simulated annealing omit maps [39], calculated by consecu-
tively omitting 10% of the model each time, showed which
parts of the model could be used for phasing. The model was
modified to include only residues sufficiently well defined in
annealed omit maps. The initial model included 815 atoms out
of a total of 1374 atoms of the complete model. 3Fo-2Fc maps
were used for cycles of model building and refinement. Typi-
cally, cycles consisted of model building, positional refinement
and B-factor refinement. Occasionally, simulated annealing was
performed. As the phases improved, more atoms were added to
the model. Initially, grouped B factors were assigned for each
C strand (one for main-chain atoms and one for side-chain
atoms). Later on, grouped B factors, and finally, individual
atomic B factors, were refined for each residue. Only manual
structure modifications that resulted in a lower Rfree value after
refinement were accepted. When R and Rfree reached 31.1%
and 36.4% respectively, the resolution was extended to 2.25 A
and finally to 2 A. Water molecules were added by using the
X-solvate utility of QUANTA 4.1. This approach identified
peaks higher than 3cr in an Fo-Fc map and waters were placed
in cases consistent with the existence of hydrogen bonds of
reasonable length and geometry. Both occupancies and tem-
perature factors were refined for the water molecules. Water
molecules having corresponding 2Fo-F c density <l1r, or high
B factors after the refinement, were eliminated from the
model. The current model has an R factor of 21.8% and an
Rfree of 29.1%. Table 1 summarizes the crystallographic data
and refinement statistics. Coordinates are being deposited in
the Brookhaven Protein Data Bank.
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